(Q36694177)

15 August 2017

Phase I dose escalation and pharmacokinetic study of pluronic polymer-bound doxorubicin (SP1049C) in patients with advanced cancer (English)

1 reference

15 August 2017

0 references

1 reference

S Danson

1

1 reference

15 August 2017

D Ferry

2

1 reference

15 August 2017

V Alakhov

3

1 reference

15 August 2017

J Margison

4

1 reference

15 August 2017

D Kerr

5

1 reference

15 August 2017

D Jowle

6

1 reference

15 August 2017

M Brampton

7

1 reference

15 August 2017

G Halbert

8

1 reference

15 August 2017

M Ranson

9

1 reference

15 August 2017

language of work or name

English

0 references

publication date

1 June 2004

1 reference

British Journal of Cancer

15 August 2017

1 reference

15 August 2017

90

1 reference

15 August 2017

11

1 reference

15 August 2017

2085-2091

1 reference

Pluronic block copolymers for overcoming drug resistance in cancer.

15 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2409484

Mechanism of sensitization of MDR cancer cells by Pluronic block copolymers: Selective energy depletion

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2409484

Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin]: first member of a new class of chemotherapeutic agents-drug-polymer conjugates. Cancer Research Campaign Phase I/II Committee

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2409484

Anthracycline antibiotics non-covalently incorporated into the block copolymer micelles: in vivo evaluation of anti-cancer activity.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2409484

Initial clinical (phase I) trial of TLC D-99 (doxorubicin encapsulated in liposomes).

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2409484

Pharmacokinetics of anthracyclines

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2409484

Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2409484

Phase II study of pegylated liposomal doxorubicin (Caelyx) as induction chemotherapy for patients with squamous cell cancer of the head and neck

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2409484

Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL/CAELYX) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: a study by the EORTC Soft Tissue and Bone Sarcoma Group

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2409484

Comparative pharmacokinetics of escalating doses of doxorubicin in patients with metastatic breast cancer

5 September 2018

1 reference

Crossref

https://api.crossref.org/works/10.1038%2FSJ.BJC.6601856

Treatment of advanced breast cancer with sterically stabilized liposomal doxorubicin: results of a multicenter phase II trial

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1038%2FSJ.BJC.6601856

Phase II trial of doxil for patients with metastatic melanoma refractory to frontline therapy

21 January 2018

1 reference

12 December 2020

Phase II trial of liposomal encapsulated doxorubicin in patients with advanced renal cell carcinoma

1 reference

12 December 2020

A phase II trial of doxorubicin HCl Liposome Injection in patients with advanced pancreatic adenocarcinoma

1 reference

12 December 2020

Hypersensitizing effect of pluronic L61 on cytotoxic activity, transport, and subcellular distribution of doxorubicin in multiple drug-resistant cells

1 reference

12 December 2020

Preclinical toxicology of a novel polymeric antitumour agent: HPMA copolymer-doxorubicin (PK1)

1 reference

12 December 2020

Identifiers

DOI

10.1038/SJ.BJC.6601856

0 references

1 reference

15 August 2017

PubMed publication ID

15150584

1 reference